Spinal MetastasesSpinal TumorRadiotherapySeparation Surgery
Investigational drug(s) / intervention(s)
radiotherapy
radiotherapy: The patients receive radiotherapy after the separation surgery.
Study summary
The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age over 18 years old, gender not limited;
2. The patient has undergone separation surgery within 3 weeks;
3. The pathological result of the separation surgery site of the patient indicates that the lesion is a metastatic tumor, and the primary lesion is located outside the spine;
4. The expected survival period is ≥ 6 months;
5. The patient has signed the informed consent form.
Exclusion Criteria:
1. Patients with poor general condition and those who are intolerant to radiotherapy, chemotherapy, and targeted therapy;
2. Patients whose treatment segments have not received any other surgical treatment or radiotherapy;
3. Patients who participated in other clinical trials of drugs or medical devices within 3 months before enrollment;
4. Other situations judged by the investigator as making the subject unsuitable for enrollment.
Primary outcome measure(s)
Progression-Free Survival (PFS) — Baseline up to 24 months. Time from the date of surgery to the first documented disease progression or death from any cause, whichever occurs first.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.